Compare AUB & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUB | SYRE |
|---|---|---|
| Founded | 1902 | 2013 |
| Country | United States | United States |
| Employees | 3064 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.9B |
| IPO Year | N/A | 2015 |
| Metric | AUB | SYRE |
|---|---|---|
| Price | $38.02 | $69.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $41.88 | ★ $85.08 |
| AVG Volume (30 Days) | 936.8K | ★ 1.3M |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.16 | N/A |
| Revenue Next Year | $4.59 | N/A |
| P/E Ratio | $19.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.11 | $12.29 |
| 52 Week High | $42.18 | $75.00 |
| Indicator | AUB | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 55.08 | 61.85 |
| Support Level | $34.59 | $30.39 |
| Resistance Level | $39.26 | $74.92 |
| Average True Range (ATR) | 0.88 | 4.51 |
| MACD | -0.05 | -0.38 |
| Stochastic Oscillator | 42.93 | 59.54 |
Atlantic Union Bankshares Corp is a financial and bank holding company based in the U.S. Through its community bank subsidiary and non-bank financial services affiliates, the company provides financial services, including banking, trust, and wealth management. It offers consumers and businesses a wide range of banking and related financial services, including checking, savings, certificates of deposit, and other depository services, as well as loans for commercial, industrial, residential mortgage, and consumer purposes. The company operates through two reportable operating segments: Wholesale Banking and Consumer Banking, with corporate support functions such as corporate treasury and others included in Corporate Other. It derives maximum revenue from the Wholesale Banking segment.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.